Diabetes, Diabetic Retinopathy, and Inflammatory Disorders

ABSTRACT

This review summarizes the impact of systemic and ocular inflammatory disorders on diabetes mellitus (DM) and diabetic retinopathy (DR). Local inflammation is a key pathology in diabetic retinopathy (DR) and is also an evolving target for clinical therapy. The legacy effects of local inflammation at the intracellular level make DR a persistent self-driven vicious process. Ocular inflammation is accompanied as well as incited by systemic inflammation due to diabetes mellitus (DM) itself. Over the years, a multitude of studies have evaluated the impact of systemic inflammatory disorders (SIDs, like rheumatoid arthritis, lupus, psoriasis, etc.) and anti-inflammatory drugs prescribed for managing them on manifestations of DM. Recent studies have indicated increased insulin resistance to be a result of chronic inflammation, and the anti-inflammatory drugs to have a protective effect towards DM. Very few studies have evaluated the impact of SIDs on DR. Furthermore, the evidence from these studies is conflicting, and while local anti-inflammatory therapy has shown a lot of clinical potential for use in DR, the results of systemic anti-inflammatory therapies have been inconsistent. The impact of local ocular inflammation due to uveitis on DR is a crucial aspect that has not been evaluated well at present. Initial pre-clinical studies and small-sized clinical reports have shown a strong and positive relationship between the presence of uveitis and the severity of DR as well as its progression, while larger cross-sectional patient surveys have refuted the same. The long term impact of ocular inflammation due to uveitis on DR needs to be studied while adjusting for confounders.

KEYWORDS:

• Anti-inflammatory drugs
• diabetes mellitus
• diabetic retinopathy
• inflammation
• uveitis

Disclosure statement

No potential conflict of interest was reported by the author(s).

Permission

Table 3 – Reproduced partially with permission from Copyright Clearance Center’s RightsLink® service (order number − 5471630726484) (reference − 3).

Additional information

Funding

a) BT, PG, PST, IK, PKR, MT, SB: Hyderabad Eye Research Foundation, Hyderabad, India. b) BT: DBT India Alliance Clinical Research Centre Grant awarded to IHOPE [grant number IA/CRC/19/1/610010].